Kymera Therapeutics (NASDAQ:KYMR) Insider Sells $387,328.81 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Noah Goodman sold 3,389 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $114.29, for a total transaction of $387,328.81. Following the completion of the transaction, the insider owned 47,179 shares of the company’s stock, valued at approximately $5,392,087.91. This represents a 6.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Noah Goodman also recently made the following trade(s):

• On Thursday, June 25th, Noah Goodman sold 5,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $114.00, for a total transaction of $570,000.00.
• On Monday, June 22nd, Noah Goodman sold 2,500 shares of Kymera Therapeutics stock. The shares were sold at an average price of $99.00, for a total transaction of $247,500.00.
• On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.00, for a total transaction of $121,230.00.
• On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.35, for a total transaction of $174,700.00.
• On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.50, for a total value of $723,100.00.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $113.51 on Friday. Kymera Therapeutics, Inc. has a twelve month low of $36.65 and a twelve month high of $130.05. The business has a 50-day moving average price of $87.36 and a 200 day moving average price of $83.12. The firm has a market cap of $9.34 billion, a PE ratio of -31.80 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. During the same quarter in the prior year, the firm posted ($0.82) EPS. Kymera Therapeutics’s quarterly revenue was up 55.5% compared to the same quarter last year. On average, sell-side analysts expect that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on KYMR. Loop Capital set a $97.00 price target on shares of Kymera Therapeutics in a research note on Monday, June 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Canaccord Genuity Group increased their price objective on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a report on Friday, June 26th. Bank of America lifted their target price on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Finally, B. Riley Financial boosted their target price on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $121.41.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC boosted its stake in Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares during the last quarter. Larson Financial Group LLC raised its position in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after buying an additional 349 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Kymera Therapeutics in the fourth quarter worth about $63,000. Osaic Holdings Inc. lifted its stake in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in Kymera Therapeutics by 56.3% during the first quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company’s stock worth $107,000 after acquiring an additional 463 shares during the last quarter.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Seeking Alpha upgraded Kymera Therapeutics to Buy, citing strong pipeline progress, a roughly $1.5 billion cash position, and accelerated timing for KT-621 Phase 2b topline data by year-end 2026. The article argues the oral STAT6 degrader could compete in a large atopic dermatitis market and challenge injectable therapies. Article Title
• Positive Sentiment: Another Seeking Alpha note said Kymera is building toward a key 2H 2026 inflection point, with KT-621’s Phase 2b readout seen as a major catalyst. The commentary also highlighted rapid enrollment, a strong balance sheet, and possible partnership upside. Article Title
• Neutral Sentiment: Analysts continue to rate KYMR favorably overall, with the consensus still at Moderate Buy and recent target increases from firms including Truist and Canaccord Genuity suggesting confidence in the company’s pipeline and long-term prospects.
• Negative Sentiment: Recent insider sales from CEO Nello Mainolfi, CFO Bruce N. Jacobs, and insider Noah Goodman may weigh on sentiment, as the transactions were sizable and follow additional selling earlier in the quarter. Article Title

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.